{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(10)"],"submitter":["Inoue S"],"pubmed_abstract":["<h4>Objectives</h4>The association between the response to first-line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real-world data.<h4>Methods</h4>We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial-response group was defined as patients with complete response or partial response as the best response to first-line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first-line chemotherapy.<h4>Results</h4>Seven patients (7.0%) achieved comp"],"journal":["International journal of urology : official journal of the Japanese Urological Association"],"pagination":["1449-1459"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12503202"],"repository":["biostudies-literature"],"pubmed_title":["Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma."],"pmcid":["PMC12503202"],"pubmed_authors":["Nagasaka Y","Ito F","Yuba T","Inoue S","Omi T","Yuguchi Y","Kawanishi H","Akamatsu S","Hayakawa A","Tochigi K","Kobayashi M","Shamoto N"],"additional_accession":[]},"is_claimable":false,"name":"Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.","description":"<h4>Objectives</h4>The association between the response to first-line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real-world data.<h4>Methods</h4>We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial-response group was defined as patients with complete response or partial response as the best response to first-line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first-line chemotherapy.<h4>Results</h4>Seven patients (7.0%) achieved comp","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:53:32.706Z","creation":"2026-05-06T03:13:31.824Z"},"accession":"S-EPMC12503202","cross_references":{"pubmed":["40600395"],"doi":["10.1111/iju.70162"]}}